Launch of gZetia positively impacted US business: Glenn Saldanha, GlenmarkIn an exclusive interview to ET Now, Glenn Saldanha, CMD, Glenmark, said next few quarters will be strong due to gZetia.
Glenmark Pharma surges 7% as brokerages stay upbeat post Q3 numbersBofa-ML believes that the growth momentum in the US geography is likely to sustain beyond 6-month exclusivity for cholesterol lowering drug...
- Neutral Glenmark Pharmaceuticals with a target of Rs 960: UBS
Expect base US biz to improve as a result of recent launches in dermatology. UBS has forecast a 33% EPS CAGR over FY16-18E for Glenmark Pha...